References
- Grever M. R., Kopecky K. J., Coltman C. A., Files J. C., Greenberg B. R., Hutton J. J., Talley R., Von Hoff D. D., Balcerzak S. P. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv. Rev. Fr. Hematol. 1988; 30: 457–459
- Keating M. J., Kantarjian H., Talpaz M., Redman J., Koller C., Barlogie B., Velasquez W., Plunkett W., Freireich E. J., McCredie K. B. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1988; 74: 19–25
- Cheson B. D., Bennet J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute Sponsored Working Group. Am. J. Hematol. 1988; 29: 152–163
- Keating M. J., Kantarjian H., O'Brien S., Koller C., Talpaz M., Schachner J., Childs C. C., Freireich E. J., McCredie K. B. Fludarabine: A new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J. Clin. Oncol. 1991; 9: 44–49
- Robertson L. E., Huh Y., Hirsch-Ginsberg C., Kantarjian H., O'Brien S., Koller C., McCredie K. B., Keating M. J. Clinical, immunophenotypic, and molecular analysis of the completeness of response in chronic lymphocytic leukemia after fludarabine. Blood 1990; 76(10)314a, Suppl. 1